BALDWIN PARK, Calif., Dec. 19, 2024 /PRNewswire/ -- StemCyte announced a significant breakthrough in its Phase IIa clinical trial of HPC, Cord Blood (HPC, CB) for treating Post-COVID Syndrome (Long COVID). This trial results demonstrated that cord blood significantly improved fatigue...
Read More Details
Finally We wish PressBee provided you with enough information of ( StemCyte Announces Successful Phase IIa Clinical Trial Results for HPC, Cord Blood in Treating Post-COVID Syndrome: 85% of Patients Experience Complete Relief from Fatigue Symptoms )
Also on site :
- Surging travel in Europe spikes concerns over tourism's drawbacks
- Iran& 039;s key nuclear sites & 039;obliterated& 039; by US airstrikes, Trump says
- PRT vs PCC Dream11 Prediction Today Match, Dream11 Team Today, Fantasy Cricket Tips, Playing XI, Pitch Report, Injury Update- ECS T10 Czechia Premier 2025, Qualifier 1